Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$150.37
+0.0%
$135.06
$77.58
$156.92
$370.89B0.2110.87 million shs4.39 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$61.16
$58.29
$30.81
$65.00
$9.10B1.22961,270 shs986,686 shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.42
-0.1%
$26.06
$23.58
$29.21
$162.16B0.3434.82 million shs23.78 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%+1.40%+16.92%+25.94%+77.77%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%+2.22%+5.32%+32.01%+85.22%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+1.68%+6.43%+10.78%+14.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$150.37
+0.0%
$135.06
$77.58
$156.92
$370.89B0.2110.87 million shs4.39 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$61.16
$58.29
$30.81
$65.00
$9.10B1.22961,270 shs986,686 shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.42
-0.1%
$26.06
$23.58
$29.21
$162.16B0.3434.82 million shs23.78 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%+1.40%+16.92%+25.94%+77.77%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%+2.22%+5.32%+32.01%+85.22%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+1.68%+6.43%+10.78%+14.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$148.60-1.18% Downside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.50
Moderate Buy$86.0040.61% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.28-0.50% Downside

Current Analyst Ratings Breakdown

Latest PCVX, PFE, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOverweight$150.00 ➝ $170.00
8/31/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
UpgradeHold (C-)Hold (C)
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOutperform$155.00 ➝ $180.00
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$145.00 ➝ $170.00
8/21/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$140.00 ➝ $160.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOutperform$142.00 ➝ $170.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$145.00 ➝ $175.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DowngradeOutperformSector Perform$142.00 ➝ $150.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
UpgradeEqual WeightOverweight$116.00 ➝ $179.00
8/19/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DowngradeStrong-BuyHold
(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.71$11.43 per share13.16$21.22 per share7.09
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$20.51 per shareN/A
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.59$4.39 per share6.47$15.26 per share1.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25120.3015.576.544.77%16.73%6.13%10/29/2026 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$7.63N/AN/AN/AN/A-37.56%-33.62%11/3/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7637.409.671.916.80%19.63%8.46%11/3/2026 (Estimated)

Latest PCVX, PFE, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$2.06-$1.97+$0.09-$1.97$12.50 millionN/A
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.26%+5.75%272.00%14 Years
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.05%-13.20%226.32%16 Years

Latest PCVX, PFE, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.61%9/15/20269/15/202610/7/2026
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
5.72
5.72
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.30%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160148.80 million143.89 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

This Is What I'd Do With Pfizer Stock Right Now
The Second Act of Biotech
Amundi Sells 7,291,854 Shares of Pfizer Inc. $PFE
Saudi Central Bank Increases Stock Position in Pfizer Inc. $PFE
Rose Capital Advisors LLC Invests $905,000 in Pfizer Inc. $PFE
Pfizer (PFE) and Its Peers Head to Head Analysis
Pfizer Ramps Up Obesity And Eczema Bets, Investors Watch
Wall Street Zen Downgrades Pfizer (NYSE:PFE) to Hold
Pfizer (NYSE:PFE) Downgraded by Wall Street Zen to "Hold"
Pfizer (NYSE:PFE) Shares Down 1.4% - What's Next?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$150.37 +0.04 (+0.03%)
As of 09/4/2026 03:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$61.16 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Pfizer stock logo

Pfizer NYSE:PFE

$28.42 -0.03 (-0.11%)
As of 09/4/2026 03:58 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.